Many pandemic issues have been swirling around in our country, and most have received extensive media coverage, most notably vaccine hesitancy/resistance, the Delta variant, and the continuing extreme importance of masking. Another is the collective angst over the time it is taking the FDA to issue full approvals of the earliest vaccines to apply for it. (It is anticipated that at least one vaccine will have received this by the time this editorial appears.)

In the background, not exactly sotto voce but receiving less print, is the question of whether the US government might exercise its so-called march-in authority on the relevant patents. Its statutory footing and operative domain are often misunderstood, and here I seek to clarify this for our readers. I am motivated to do so because I did not initially understand it either.

许多大流行问题一直在我们国家四处蔓延，大多数问题都得到了媒体的广泛报道，最显着的是疫苗犹豫/抗药性、Delta 变体以及持续的极端重要性的掩蔽。另一个是对 FDA 全面批准最早申请疫苗的时间的集体焦虑。（预计到本社论出现时，至少会有一种疫苗收到此信息。）

在背景中，不完全是口是心非，但印刷量较少，是美国政府是否可能对相关专利行使所谓的进军权力的问题。它的法定基础和运作领域经常被误解，在这里我试图为我们的读者澄清这一点。我有动力这样做，因为我最初也不理解它。